Cara Therapeutics Announces Proposed Offering of Common Stock
July 27, 2015 16:20 ET
|
Cara Therapeutics
SHELTON, Conn., July 27, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Announces Positive Results From Phase 2 Trial in Uremic Pruritus
July 23, 2015 07:00 ET
|
Cara Therapeutics
Novel peripheral kappa opioid I.V. CR845 achieved statistically-significant results on primary endpoint of reducing worst itch intensity
Trial demonstrated statistically significant results on...
Cara Therapeutics Completes Enrollment of Phase 2 Trial of I.V. CR845 in Uremic Pruritus
June 23, 2015 08:00 ET
|
Cara Therapeutics
Top-line data expected in early 3Q'15
SHELTON, Conn., June 23, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and...
Cara Therapeutics to Sponsor Symposium and Present Poster at the College on Problems of Drug Dependence 77th Annual Meeting
June 10, 2015 08:00 ET
|
Cara Therapeutics
SHELTON, Conn., June 10, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
Cara Therapeutics to Present at the 2015 International Conference on Opioids
June 05, 2015 08:00 ET
|
Cara Therapeutics
SHELTON, Conn., June 5, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
Cara Therapeutics Reports First Quarter 2015 Financial Results
May 12, 2015 16:01 ET
|
Cara Therapeutics
– End-of-Phase 2 Meeting With FDA Informs Phase 3 Clinical Development Program for Novel Kappa Opioid I.V. CR845 –
– Conference Call Today at 4:30 p.m. ET –
SHELTON,...
Cara Therapeutics to Present at American Pain Society 34th Annual Scientific Meeting
May 06, 2015 08:00 ET
|
Cara Therapeutics
Pain experts to discuss kappa opioid receptor agonists and latest developments in pain management
Company to present positive data from Phase 2, human abuse liability studies of I.V. CR845...
Cara Therapeutics to Announce First Quarter 2015 Financial Results on May 12, 2015
May 05, 2015 16:30 ET
|
Cara Therapeutics
SHELTON, Conn., May 5, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
Cara Therapeutics to Present at 3rd Conference on the Therapeutic Potential of Kappa Opioids
April 15, 2015 08:00 ET
|
Cara Therapeutics
Company to present data from human abuse liability (HAL) study of I.V. CR845
SHELTON, Conn., April 15, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology...
Cara Therapeutics to Webcast Presentation at 14th Annual Needham Healthcare Conference
April 07, 2015 08:00 ET
|
Cara Therapeutics
SHELTON, Conn., April 7, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...